Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.

ABSTRACT:

Rationale

Debate exists about the immunogenicity and protective efficacy of antibodies produced by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in chronic obstructive pulmonary disease (COPD). The 7-valent diphtheria-conjugated pneumococcal polysaccharide vaccine (PCV7) induces a more robust immune response than PPSV23 in healthy elderly adults.

Objectives

We hypothesized that serotype-specific IgG antibody concentration and functional antibody activity would be superior after PCV7 vaccination compared with PPSV23 in moderate to severe COPD. We also posited that older age and prior PPSV23 vaccination would be associated with reduced vaccine responsiveness.

Methods

One hundred twenty patients with COPD were randomized to PPSV23 (63 subjects) or PCV7 (57 s

SUBMITTER: Dransfield MT 

PROVIDER: S-EPMC2742743 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature